Most candidate Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccines utilise S protein or its derivatives as the immunogen [2] and a number of antibodies targeting the SARS-CoV-2 S protein are under development for COVID-19 treatment [3]. Here, PROS1 is linked to COVID-19.